Molecular variants of epidermal growth factor in malignant astrocytoma

R. K. Rao, M. Shantaram, A. R. Aroor, A. Raja, Thomas P Davis, A. Rao

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The present study has measured EGF levels in primary brain tumor tissues. EGF levels were measured by specific radioimmunoassay (RIA) and further analyzed by reversed-phase high performance liquid chromatography (RP-HPLC) followed by RIA and radioreceptor binding. The levels of EGF-like immunoreactivity (EGF-LI) in astrocytoma-IV tumors were fourfold greater than those in normal brain tissues. In astrocytoma-II and astrocytoma-III tumors, however, levels of EGF-LI were not different from those in normal brain. HPLC analysis of extracts from normal brain tissue and astrocytoma-II showed one peak of EGF-LI that coeluted with standard human EGF (retention time 22 min). Interestingly, EGF-LI in extracts of astrocytoma-IV tumors eluted in two distinct peaks with retention times of 24 and 26 min (Astro-A and Astro-B, respectively). Materials in both Astro-A and Astro-B peaks reduced the specific binding of [125I]hEGF to EGF receptors in human placental membranes. These studies demonstrate elevated levels of EGF-LI in malignant astrocytoma, but not in benign tumors. Furthermore, two different EGF-like molecules that are different from native EGF are present in malignant astrocytoma.

Original languageEnglish (US)
Pages (from-to)179-181
Number of pages3
JournalPeptides
Volume17
Issue number1
DOIs
StatePublished - 1996

Fingerprint

Astrocytoma
Epidermal Growth Factor
Tumors
Brain
Tissue
Radioimmunoassay
Neoplasms
High Pressure Liquid Chromatography
High performance liquid chromatography
Reverse-Phase Chromatography
Brain Neoplasms
Membranes

Keywords

  • Brain
  • Cancer
  • EGF
  • Human
  • Receptor
  • Transformation
  • Tumor

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Molecular variants of epidermal growth factor in malignant astrocytoma. / Rao, R. K.; Shantaram, M.; Aroor, A. R.; Raja, A.; Davis, Thomas P; Rao, A.

In: Peptides, Vol. 17, No. 1, 1996, p. 179-181.

Research output: Contribution to journalArticle

Rao, RK, Shantaram, M, Aroor, AR, Raja, A, Davis, TP & Rao, A 1996, 'Molecular variants of epidermal growth factor in malignant astrocytoma', Peptides, vol. 17, no. 1, pp. 179-181. https://doi.org/10.1016/0196-9781(95)02087-X
Rao, R. K. ; Shantaram, M. ; Aroor, A. R. ; Raja, A. ; Davis, Thomas P ; Rao, A. / Molecular variants of epidermal growth factor in malignant astrocytoma. In: Peptides. 1996 ; Vol. 17, No. 1. pp. 179-181.
@article{2ef6cbb30eb14ae5a5e0e2955e349248,
title = "Molecular variants of epidermal growth factor in malignant astrocytoma",
abstract = "The present study has measured EGF levels in primary brain tumor tissues. EGF levels were measured by specific radioimmunoassay (RIA) and further analyzed by reversed-phase high performance liquid chromatography (RP-HPLC) followed by RIA and radioreceptor binding. The levels of EGF-like immunoreactivity (EGF-LI) in astrocytoma-IV tumors were fourfold greater than those in normal brain tissues. In astrocytoma-II and astrocytoma-III tumors, however, levels of EGF-LI were not different from those in normal brain. HPLC analysis of extracts from normal brain tissue and astrocytoma-II showed one peak of EGF-LI that coeluted with standard human EGF (retention time 22 min). Interestingly, EGF-LI in extracts of astrocytoma-IV tumors eluted in two distinct peaks with retention times of 24 and 26 min (Astro-A and Astro-B, respectively). Materials in both Astro-A and Astro-B peaks reduced the specific binding of [125I]hEGF to EGF receptors in human placental membranes. These studies demonstrate elevated levels of EGF-LI in malignant astrocytoma, but not in benign tumors. Furthermore, two different EGF-like molecules that are different from native EGF are present in malignant astrocytoma.",
keywords = "Brain, Cancer, EGF, Human, Receptor, Transformation, Tumor",
author = "Rao, {R. K.} and M. Shantaram and Aroor, {A. R.} and A. Raja and Davis, {Thomas P} and A. Rao",
year = "1996",
doi = "10.1016/0196-9781(95)02087-X",
language = "English (US)",
volume = "17",
pages = "179--181",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Molecular variants of epidermal growth factor in malignant astrocytoma

AU - Rao, R. K.

AU - Shantaram, M.

AU - Aroor, A. R.

AU - Raja, A.

AU - Davis, Thomas P

AU - Rao, A.

PY - 1996

Y1 - 1996

N2 - The present study has measured EGF levels in primary brain tumor tissues. EGF levels were measured by specific radioimmunoassay (RIA) and further analyzed by reversed-phase high performance liquid chromatography (RP-HPLC) followed by RIA and radioreceptor binding. The levels of EGF-like immunoreactivity (EGF-LI) in astrocytoma-IV tumors were fourfold greater than those in normal brain tissues. In astrocytoma-II and astrocytoma-III tumors, however, levels of EGF-LI were not different from those in normal brain. HPLC analysis of extracts from normal brain tissue and astrocytoma-II showed one peak of EGF-LI that coeluted with standard human EGF (retention time 22 min). Interestingly, EGF-LI in extracts of astrocytoma-IV tumors eluted in two distinct peaks with retention times of 24 and 26 min (Astro-A and Astro-B, respectively). Materials in both Astro-A and Astro-B peaks reduced the specific binding of [125I]hEGF to EGF receptors in human placental membranes. These studies demonstrate elevated levels of EGF-LI in malignant astrocytoma, but not in benign tumors. Furthermore, two different EGF-like molecules that are different from native EGF are present in malignant astrocytoma.

AB - The present study has measured EGF levels in primary brain tumor tissues. EGF levels were measured by specific radioimmunoassay (RIA) and further analyzed by reversed-phase high performance liquid chromatography (RP-HPLC) followed by RIA and radioreceptor binding. The levels of EGF-like immunoreactivity (EGF-LI) in astrocytoma-IV tumors were fourfold greater than those in normal brain tissues. In astrocytoma-II and astrocytoma-III tumors, however, levels of EGF-LI were not different from those in normal brain. HPLC analysis of extracts from normal brain tissue and astrocytoma-II showed one peak of EGF-LI that coeluted with standard human EGF (retention time 22 min). Interestingly, EGF-LI in extracts of astrocytoma-IV tumors eluted in two distinct peaks with retention times of 24 and 26 min (Astro-A and Astro-B, respectively). Materials in both Astro-A and Astro-B peaks reduced the specific binding of [125I]hEGF to EGF receptors in human placental membranes. These studies demonstrate elevated levels of EGF-LI in malignant astrocytoma, but not in benign tumors. Furthermore, two different EGF-like molecules that are different from native EGF are present in malignant astrocytoma.

KW - Brain

KW - Cancer

KW - EGF

KW - Human

KW - Receptor

KW - Transformation

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=0030058379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030058379&partnerID=8YFLogxK

U2 - 10.1016/0196-9781(95)02087-X

DO - 10.1016/0196-9781(95)02087-X

M3 - Article

C2 - 8822528

AN - SCOPUS:0030058379

VL - 17

SP - 179

EP - 181

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 1

ER -